马玲,王婧雅,徐倩伟,余小林

• 1:新疆医科大学研究生学院
• 2:新疆维吾尔自治区人民医院心脏及泛血管诊疗中心
• 3:新疆心脏血管稳态与再生医学研究重点实验室

摘要(Abstract)：

目前，经导管主动脉瓣置换术（TAVR）已不仅仅是外科高危重度主动脉瓣狭窄（AS）患者的优选替代方案，中危和低危AS患者也有所获益。近1/2的AS患者合并冠状动脉疾病（CAD），因此在TAVR治疗重度AS合并CAD的患者中行经皮冠状动脉介入治疗（PCI）成为临床常见需求。当前TAVR与PCI孰先孰后亦或同期进行存在较大争议。本文将对行TAVR治疗的重度AS合并慢性CAD患者行PCI的时机进行综述。

关键词(KeyWords)： 主动脉瓣狭窄;经导管主动脉瓣置换术;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 马玲,王婧雅,徐倩伟,余小林

参考文献(References)：

• [1] Faroux L, Guimaraes L, Wintzer-Wehekind J, et al. Coronary artery disease and transcatheter aortic valve replacement:JACC state-of-the-art review[J]. J Am Coll Cardiol, 2019, 74(3):362-372.DOI:10.1016/j.jacc.2019.06.012.
• [2] Malmberg M, Gunn J, Sipil?J, et al. Comparison of longterm outcomes of patients having surgical aortic valve replacement with versus without simultaneous coronary artery bypass grafting[J]. Am J Cardiol, 2020, 125(6):964-969.DOI:10.1016/j.amjcard.2019.12.015.
• [3] Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in lowrisk patients[J]. N Engl J Med, 2019, 380(18):1695-1705. DOI:10.1056/NEJMoa1814052.
• [4] Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aorticvalve replacement with a self-expanding valve in low-risk patients[J]. N Engl J Med, 2019, 380(18):1706-1715.DOI:10.1056/NEJMoa1816885.
• [5] Tarantini G, Tang G, Nai Fovino L, et al. Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions in collaboration with the ESC Working Group on Cardiovascular Surgery[J]. EuroIntervention, 2023, 19(1):37-52.DOI:10.4244/eij-d-22-00958.
• [6] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2021, 143(5):e35-e71.DOI:10.1161/cir.0000000000000932.
• [7]俞吉维，杜润，朱政斌，等.经导管主动脉瓣置换术患者冠状动脉疾病的管理与处理策略[J].中国介入心脏病学杂志，2023,31(6):452-456.DOI:10.3969/j.issn.1004-8812.2023.06.008.
• [8] Fischer J, Stef fen J, Arlart T, et al. Concomitant percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation[J]. Catheter Cardiovasc Interv, 2024,103(1):186-193.DOI:10.1002/ccd.30927.
• [9] Ochiai T, Yoon SH, Flint N, et al. Timing and outcomes of percutaneous coronary intervention in patients who underwent transcatheter aortic valve implantation[J]. Am J Cardiol, 2020,125(9):1361-1368.DOI:10.1016/j.amjcard.2020.01.043.
• [10] Park DY, Simonato M, Ahmad Y, et al. Insight i n t o the optimal timing of percutaneous coronary intervention and transcatheter aortic valve replacement[J]. Curr Probl Cardiol, 2024, 49(1 Pt A):102050.DOI:10.1016/j.cpcardiol.2023.102050.
• [11] S?ndergaard L, Popma JJ, Reardon MJ, et al. Comparison of a complete percutaneous versus surgical approach to aortic valve replacement and revascularization in patients at intermediate surgical risk:results from the randomized SURTAVI trial[J].Circulation, 2019, 140(16):1296-1305.DOI:10.1161/CIRCULATIONAHA.118.039564.
• [12] Yassen M, Moustafa A, Venkataramany B, et al.Clinical outcomes of transcatheter aortic valve replacement with and without percutaneous coronary intervention-an updated meta-analysis and systematic review[J]. Curr Probl Cardiol, 2023, 48(11):101980. DOI:10.1016/j.cpcardiol.2023.101980.
• [13] Patterson T, Clayton T, Dodd M, et al. ACTIVATION(percutaneous coronary intervention prior to transcatheter aortic valve implantation):a randomized clinical trial[J]. JACC Cardiovasc Interv, 2021, 14(18):1965-1974.DOI:10.1016/j.jcin.2021.06.041.
• [14] Witberg G, Regev E, Chen S, et al. The prognostic ef fects of coronary disease severity and completeness of revascularization on mortality in patients undergoing transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv, 2017, 10(14):1428-1435. DOI:10.1016/j.jcin.2017.04.035.
• [15] Stefanini GG, Stortecky S, Cao D, et al. Coronary artery disease severity and aortic stenosis:clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation[J]. Eur Heart J, 2014, 35(37):2530-2540.DOI:10.1093/eurheartj/ehu074.
• [16] Witberg G, Zusman O, Codner P,et al. Impact of coronary artery revascularization completeness on outcomes of patients with coronary artery disease undergoing transcatheter aortic valve replacement:a meta-analysis of studies using the residual SYNTAX score(synergy between PCI with taxus and cardiac surgery)[J]. Circ Cardiovasc Interv, 2018, 11(3):e006000.DOI:10.1161/CIRCINTERVENTIONS.117.006000.
• [17] Stephan T, Thoma E, Rattka M, et al. Impact of extent of coronary artery disease and percutaneous revascularization assessed by the SYNTAX score on outcomes following transcatheter aortic valve replacement[J]. BMC Cardiovasc Disord, 2021,21(1):568.DOI:10.1186/s12872-021-02374-y.
• [18] Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2022, 145(3):e4-e17.DOI:10.1161/CIR.0000000000001039.
• [19] Kumar A, Sammour Y, Reginauld S, et al. Adverse clinical outcomes in patients undergoing both PCI and TAVR:analysis from a pooled multi-center registry[J]. Catheter Cardiovasc Interv, 2021, 97(3):529-539.DOI:10.1002/ccd.29233.
• [20] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7):561-632.DOI:10.1093/eurheartj/ehab395.
• [21] Chakravarty T, Sharma R, Abramowitz Y, et al. Outcomes in patients with transcatheter aortic valve replacement and left main stenting:the TAVR-LM registry[J]. J Am Coll Cardiol,2016, 67(8):951-960.DOI:10.1016/j.jacc.2015.10.103.
• [22] Altibi AM, Ghanem F, Hammad F, et al. Clinical outcomes of revascularization with percutaneous coronary intervention prior to transcatheter aortic valve replacement:a comprehensive metaanalysis[J]. Curr Probl Cardiol, 2022, 47(11):101339.DOI:10.1016/j.cpcardiol.2022.101339.
• [23] van Rosendael PJ, van der Kley F, Kamperidis V, et al. Timing of staged percutaneous coronary intervention before transcatheter aortic valve implantation[J]. Am J Cardiol, 2015, 115(12):1726-1732.DOI:10.1016/j.amjcard.2015.03.019.
• [24] Faroux L, Campelo-Parada F, Munoz-Garcia E, et al. Procedural characteristics and late outcomes of percutaneous coronary intervention in the workup pre-TAVR[J]. JACC Cardiovasc Interv, 2020, 13(22):2601-2613.DOI:10.1016/j.jcin.2020.07.009.
• [25] Avvedimento M, Campelo-Parada F, Munoz-Garcia E, et al.Late bleeding events in patients undergoing percutaneous coronary intervention in the workup pre-TAVR[J]. JACC Cardiovasc Interv, 2023, 16(17):2153-2164.DOI:10.1016/j.jcin.2023.06.037.
• [26] Persits I, Layoun H, Kondoleon NP, et al. Impact of untreated chronic obstructive coronary artery disease on outcomes after transcatheter aortic valve replacement[J]. Eur Heart J, 2024,45(21):1890-1900. DOI:10.1093/eurheartj/ehae019.
• [27] Minten L, Wissels P, McCutcheon K, et al. The effect of coronary lesion complexity and preprocedural revascularization on 5-year outcomes after TAVR[J]. JACC Cardiovasc Interv, 2022, 15(16):1611-1620.DOI:10.1016/j.jcin.2022.06.019.
• [28] Stefanini GG, Gitto M. The dilemma of CAD in TAVR candidates:useful to find it, useless to treat it?[J]. JACC Cardiovasc Interv, 2022, 15(16):1621-1623.DOI:10.1016/j.jcin.2022.07.002.
• [29] Khan SU, Dani SS, Ganatra S, et al. Percutaneous coronary intervention before transcatheter aortic valve implantation:a propensity score matched analysis[J]. Cardiovasc Revasc Med, 2024. DOI:10.1016/j.carrev.2024.03.011. Online ahead of print.
• [30]赵建明，李峰，张华，等.主动脉瓣疾病合并冠心病患者行经导管主动脉瓣置换术联合经皮冠状动脉介入治疗效果分析[J].中华实用诊断与治疗杂志，2023, 37(12):1200-1204. DOI:10.13507/j.issn.1674-3474.2023.12.003.
• [31] Nai Fovino L, Scotti A, Massussi M, et al. Incidence and feasibility of coronary access after transcatheter aortic valve replacement[J]. Catheter Cardiovasc Interv, 2020, 96(5):E535-E541.DOI:10.1002/ccd.28720.
• [32] Gon?alves M, de Araújo Gon?alves P, Campante Teles R, et al. Low rate of invasive coronary angiography following transcatheter aortic valve implantation:real-world prospective cohort findings[J]. Cardiovasc Revasc Med, 2021, 28:42-49.DOI:10.1016/j.carrev.2020.07.030.
• [33] Millan-Iturbe O, Sawaya FJ, L?nborg J, et al. Coronary artery disease, revascularization, and clinical outcomes in transcatheter aortic valve replacement:real-world results from the East Denmark Heart Registry[J]. Catheter Cardiovasc Interv, 2018, 92(4):818-826.DOI:10.1002/ccd.27440.
• [34] Tanaka A, Jabbour RJ, Testa L, et al. Incidence, technical safety, and feasibility of coronary angiography and intervention following self-expanding transcatheter aortic valve replacement[J]. Cardiovasc Revasc Med,2019,20(5):371-375DOI:.10.1016/j.carrev.2019.01.026.
• [35] Kumar V, Sandhu GS, Harper CM, et al. Analysis of the changing economics of US hospital transcatheter aortic valve replacement programs[J]. Mayo Clin Proc,2021,96(1):174-182. DOI:10.1016/j.mayocp.2020.04.012.
• [36]张洪亮，刘庆荣，陈阳，等.经导管主动脉瓣置换术后行经皮冠状动脉介入治疗初步经验[J].中国介入心脏病学杂志，2023,31(6):427-431.DOI:10.3969/j.issn.1004-8812.2023.06.004.